용석범 (한국생명공학연구원) | 한빛사논문 > 한빛사

한빛사논문

조회751

한국생명공학연구원

CV File 42 kb

ACS Mater. Lett., Publication Date:March 21, 2024 | https://doi.org/10.1021/acsmaterialslett.3c01642 Microbiome-Derived Lipid Nanoparticles for Improved Immunogenicity of mRNA Vaccines

Seok-Beom Yong^1*, Ok Hyun Park¹, and Sungchan Cho^1,2

¹Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 28116, Chungcheongbuk-do, Republic of Korea

²Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (KUST), Daejeon 34113, Republic of Korea

*Corresponding Author : Seok-Beom Yong

Abstract

Lipid nanoparticle (LNP)-based mRNA vaccines have achieved great success during the COVID-19 pandemic. However, the current formulation of LNPs requires additional optimization for the improvement of antigen-specific immunity and the vaccination effect. The microbiome and its metabolites have shown beneficial effects on the host immune systems, especially on the induction of antigen-specific T cells and the antibody response of B cells. Herein, microbiome-derived LNPs (mbm-LNPs) are developed via the incorporation of short-chain fatty acids, the microbiome metabolites, into LNPs. mbm-LNPs-mediated delivery of ovalbumin and COVID-19 spike mRNA significantly improves antigen-specific CD8+ T cell and B cell responses compared to the approved LNP formulation. In vivo study in a tumor model exhibits enhanced protective effects of mbm-LNP against the antigen-expressing tumor cells and generalizes the immune-improving effect of mbm-LNP on the various ionizable lipids. Conclusively, this study suggests that microbiome metabolites could be an adjuvant for improving antigen-specific adaptive immune responses of mRNA vaccines.

논문정보

형식Research article
게재일2024년 03월 (BRIC 등록일 2024-04-08)
연구진국내 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기